U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124936) titled 'A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma' on Aug. 11.
Brief Summary: The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
Study Start Date: July 30
Stu...